OpenZeppelin and Axelar Introduce OpenBridge, Composable Crosschain Security for Onchain Applications

BERLIN--(BUSINESS WIRE)--Jun 13, 2025--
OpenZeppelin, the most trusted provider of open source standards for building secure blockchain applications, and Interop Labs, the initial developer of Axelar, a leading web3 interoperability platform, announced today the launch of OpenBridge, an open source framework for developers to integrate multiple interoperability protocols in a single message. OpenBridge is built on the ERC-7786 crosschain messaging standard, recently endorsed by the Ethereum Foundation's Interoperability Working Group.
With OpenBridge, an application can combine multiple interoperability protocols in a single multichain transaction, requiring verification from some or all of them before the transaction is approved. This configuration, sometimes called x of y of n, can be used to enhance security for high-value transactions.
OpenZeppelin and Interop Labs announced OpenBridge ahead of ZuBerlin, an Ethereum developer conference that will gather industry leaders, founders, and researchers working on crosschain interoperability.
'This is about giving developers composability in cross-chain, without putting any proprietary code, externally owned accounts or venture-backed middlemen in between,'said Sergey Gorbunov, CEO of Interop Labs and co-founder of Axelar protocol.'Most importantly, OpenBridge is open source, just like the ERC-7786 standard it is built upon.'
ERC-7786 provides a standard application programming interface (API) for crosschain messaging, eliminating vendor lock-in by allowing developers to switch providers or expand coverage without rewriting application logic. It has been designed to integrate with any protocol or bridge (supporting ERC-7786 natively or through gateway adapters). At present, Axelar and Wormhole connections are enabled using adapters.
Working on a similar concept to a multi-signature wallet, OpenBridge sends messages through multiple ERC-7786-compliant bridges and requires multiple confirmations before delivery. For example, OpenBridge would enable a DeFi protocol to set an added layer of security for high-value loans, requiring 2-out-of-3 interoperability protocols to confirm collateral before issuing a crosschain loan.Documentation, Solidity libraries, and reference implementations for ERC-7786 and OpenBridge are now available aterc7786.org.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250613946310/en/
CONTACT: Media Contact
Karla Vilhelem, PR Director, MarketWaves
[email protected]
(754) 215-4315
KEYWORD: GERMANY EUROPE
INDUSTRY KEYWORD: BLOCKCHAIN SOFTWARE CRYPTOCURRENCY WEB3 PROFESSIONAL SERVICES TECHNOLOGY APPS/APPLICATIONS FINTECH
SOURCE: Axelar
Copyright Business Wire 2025.
PUB: 06/13/2025 12:30 PM/DISC: 06/13/2025 12:28 PM
http://www.businesswire.com/news/home/20250613946310/en

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Upturn

16 minutes ago

• Business Upturn

AIXA Miner Unveils New Free Cloud Mining Platform Aligned with 2025 Green Tech and Smart Mining Goals

Denver, CO, USA, June 21, 2025 (GLOBE NEWSWIRE) — In a strategic move that highlights its commitment to innovation and environmental responsibility, AIXA Miner has announced the launch of its upgraded free cloud mining platform, designed for a new generation of crypto users. The announcement aligns with the growing industry focus on sustainability, smart mining technologies, and secure digital asset access, making AIXA one of the first platforms to truly meet 2025's evolving mining standards. With a user base spanning over 120 countries and a strong foundation in automated mining infrastructure, AIXA Miner enables users to mine Bitcoin, Ethereum, and other top digital assets directly from the cloud — no hardware, no technical know-how required. A More Responsible Way to Mine Crypto The 2025 crypto mining landscape is shifting rapidly. Rising concerns about energy use, network security, and environmental impact have led many miners and investors to seek alternatives to traditional hardware mining. AIXA Miner is answering that call by launching a zero-cost, carbon-conscious, and technology-forward mining platform that removes entry barriers and prioritizes both profitability and planet. Key features of the new platform include: Free mining startup trial , available to all new users , available to all new users No hardware required , mining runs via AIXA's secured cloud infrastructure , mining runs via AIXA's secured cloud infrastructure Green energy-powered data centers AI-optimized mining schedules for efficiency and speed for efficiency and speed User dashboard with real-time earnings tracking Daily payouts in USDT or crypto of choice Technological Excellence Meets Everyday Usability What sets AIXA Miner apart is its ability to blend technical innovation with everyday simplicity. The platform's mining engine is backed by AI-driven algorithms and secure server farms — yet the interface is clean, user-friendly, and mobile-responsive. Users can start mining within minutes, with just an email sign-up and zero upfront investment. The platform also offers a selection of low-entry contracts for users looking to scale up at their own pace, along with a tiered referral system to encourage community growth. Sustainability Built In AIXA Miner's infrastructure includes green-compliant energy use policies and carbon-reduction initiatives, contributing to a smarter and more sustainable crypto ecosystem. This commitment not only meets the benchmarks outlined in global crypto mining sustainability frameworks for 2025, it also reflects the values of the growing number of eco-conscious digital asset users worldwide. How to Get Started Visit Sign up with your email to activate the free mining trial Choose your preferred asset and let the cloud engine begin mining Track your earnings daily and withdraw or reinvest as desired Invite others and earn referral rewards on every new user About AIXA Miner Founded in 2020, AIXA Miner is a U.S.-based cloud mining platform powered by renewable energy and artificial intelligence. With a presence in over 200 countries and regulatory certifications, the platform delivers secure, daily-yield mining services that are easy to access and designed for long-term sustainability. For more information, visit: [ Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks and the possibility of losing funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

Business Wire

4 hours ago

• Business Wire

GE HealthCare drives innovation in theranostics with latest technological advances

CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.

Yahoo

4 hours ago

• Yahoo

Prediction: XRP Will Top $12.50 by 2028

Standard Chartered recently predicted that XRP would hit a price of $12.50 by 2028, implying a $750 billion total market capitalization. Given new regulatory clarity for crypto, XRP could see rapid growth in its cross-border payments business. New spot ETFs, tentatively scheduled for Q4 2025, could provide a boost to XRP. 10 stocks we like better than XRP › At the end of 2024, XRP (CRYPTO: XRP) suddenly went parabolic, eventually hitting a new 52-week high of $3.39 in January. After going up 600% in an astonishingly short period of time, it looked like XRP might finally be headed to the moon. So it's perhaps no surprise that a number of analysts and investors have put out some fairly aggressive price targets for XRP. For example, Standard Chartered recently predicted that XRP could hit a price of $12.50 by 2028. So are they right? To hit a price of $12.50 in just three years, a lot has to go right for XRP. So you can think of this as the ultimate bull-case scenario. Let's do the quick math. Given XRP's current price of $2.30, investors would need XRP to increase in value by a multiple of approximately 5.5 by 2028. The current market cap of XRP is $136 billion, so that implies that XRP will be a $750 billion asset within just three years. That's more than double the current market cap of Ethereum (CRYPTO: ETH). According to the numbers used by Standard Chartered, XRP will be worth $5.50 by the end of this year, $8 by the end of 2026, $10.40 by the end of 2027, and $12.50 by the end of 2028. In all fairness to Standard Chartered, the $12.50 price forecast came out in April, which is when the first real effects of tariffs began to be felt. And XRP was coming off a head-spinning performance after the election, so the future looked very bright indeed. But here's the reality: XRP will need to quadruple in value by the end of next year, amid a backdrop of global macroeconomic uncertainty. That's a tall task for any cryptocurrency. The good news is that XRP appears to have a number of solid growth catalysts that could catapult it forward. The first and most important of these is continued growth in XRP's primary use case: Facilitating cross-border payments. Using the XRP blockchain, it's cheaper, faster, and easier to do so than with traditional financial tools. So the big idea here is that financial institutions around the world will continue to integrate XRP into their payment mechanisms, thereby boosting demand for XRP. The second important growth catalyst is the imminent launch of new spot XRP ETFs, similar to the spot ETFs for Bitcoin (CRYPTO: BTC) that launched in January 2024. The thinking here is that these ETFs will be a way for both retail and institutional investors to get easy exposure to XRP. In theory, as much as $8 billion will pour into these new spot ETFs, and the price of XRP will move upward accordingly. The third and final growth catalyst is what Standard Chartered refers to as "regularity clarity." Ripple, the company behind the XRP token, was under a regulatory cloud during the Biden administration. In December 2020, the SEC claimed that XRP was a security, and that led to a bruising four-year court battle. However, under the pro-crypto Trump administration, all those regulatory issues appear to have been swept away, thereby allowing XRP to go back to business as usual. On the surface, each of those growth catalysts is quite compelling. However, if you peer under the surface, there's reason for concern. For example, there are now serious questions being raised about the potential effect of stablecoins on XRP. Many now think that dollar-pegged stablecoins will eventually supplant XRP as a way to send cross-border payments. If that's the case, then investors will need to downsize future growth expectations for XRP. Moreover, it's not entirely clear how much demand there will be for the new spot XRP ETFs. Based on recent data from CoinShares, which tracks institutional fund flows into different crypto assets, it now looks like money is moving out of XRP. That makes sense, given that XRP is down 32% from its January highs. At the end of the day, XRP is very much a boom-or-bust crypto. If you take a big-picture view, the chart for XRP should be reason for concern. There have been two massive rallies (in 2018 and after the 2024 election), and one mini-rally in 2020-2021. Other than that, XRP hasn't done much at all. In fact, in more than a decade, XRP has never once traded higher than $3.84, and this happened more than seven years ago. Thus, hitting a future price target of $12.50 could be quite challenging. Going forward, one key to unlocking future price action in XRP will be the launch of the new spot ETFs. If they under-promise and over-deliver, then I'll be much more likely to ratchet up my price target for XRP going forward. Before you buy stock in XRP, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and XRP wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Dominic Basulto has positions in Bitcoin, Ethereum, and XRP. The Motley Fool has positions in and recommends Bitcoin, Ethereum, and XRP. The Motley Fool has a disclosure policy. Prediction: XRP Will Top $12.50 by 2028 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data